Editas Medicine, Inc. (EDIT) vs NeoGenomics, Inc. (NEO)

A side-by-side comparison of Editas Medicine, Inc. and NeoGenomics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — EDIT vs NEO

growth of $100 · dividends reinvested · last 10y
EDIT -79.3% (-14.6%/yr)NEO +134.5% (+8.9%/yr)NEO compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020182020202220242026$21$234
EDIT NEO

EDIT vs NEO: by the numbers

  • •NEO is the larger company ($440M vs $423M market cap).
  • •Both run net losses; NEO's is the smaller (-6.77% vs -157.32% net margin).
  • •NEO grew revenue faster over the past five years (9.41% vs -10.34% CAGR).

Metrics side by side

Valuation

MetricEDITNEO
Forward P/EN/A93.64
P/S ratio8.990.57
P/B ratio4.020.56

Profitability

MetricEDITNEO
Gross margin100.00%42.92%
Operating margin-245.15%-8.63%
Net margin-157.32%-6.77%
ROE-70.24%-6.60%
ROIC-48.61%-5.29%

Growth (annualized)

MetricEDITNEO
Revenue CAGR (5Y)-10.34%9.41%
Total return CAGR (5Y)-40.76%-15.14%

Frequently asked

Which has grown faster, EDIT or NEO?
Over the past five years, NEO grew revenue faster — EDIT at a -10.34% CAGR versus NEO at 9.41%.
How have EDIT and NEO total returns compared?
Over the past 10 years, EDIT delivered -15.75% and NEO delivered 8.90% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.